Literature DB >> 2906152

Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics.

A S Undie1, E Friedman.   

Abstract

In an attempt to understand the nature of the interactions between D1 and D2 dopamine subsystems as well as between dopamine and acetylcholine, catalepsy was assessed in rats following various drug treatments. The D1-specific antagonist SCH23390 (0.1 mg/kg) produced prompt, potent and brief (less than 90 min) catalepsy with an ED50 of 0.105 mg (0.3 mumol)/kg. Conversely, fluphenazine (0.1 mg/kg), spiroperidol (0.1 mg/kg), and haloperidol (0.2 mg/kg) all had comparably potent but more slowly rising and prolonged (greater than 240 min) effects. The action of SCH23390 was synergistic with spiroperidol, inhibited by apomorphine or atropine, unaffected by mecamylamine, and markedly potentiated by pilocarpine. However, pilocarpine was unable to significantly potentiate the action of fluphenazine or spiroperidol. It is inferred that SCH23390 differs from the classical neuroleptics in its mechanism of cataleptogenicity, that there is a cholinergic link with the D1 dopamine system, and further, that there may be a difference in the nature or impact of the cholinergic interaction with the D1 and D2 dopamine systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906152     DOI: 10.1007/BF00216056

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

Review 1.  Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems.

Authors:  J L Waddington
Journal:  Biochem Pharmacol       Date:  1986-11-01       Impact factor: 5.858

2.  Anticholinergics promote neuroleptic-induced tardive dyskinesia.

Authors:  R L Borison; B I Diamond
Journal:  Adv Biochem Psychopharmacol       Date:  1980

3.  Catatonic behavior induced by haloperidol, increased by retesting and elicited without drug in rats.

Authors:  L F de Sousa Moreira; M C Pinheiro; J Masur
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

Review 4.  Two dopamine receptors: biochemistry, physiology and pharmacology.

Authors:  J C Stoof; J W Kebabian
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

5.  Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.

Authors:  C Erzin-Waters; P Muller; P Seeman
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

6.  Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.

Authors:  E J Hess; L J Albers; H Le; I Creese
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

7.  Catalepsy induced by SCH 23390 in rats.

Authors:  M Morelli; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1985-11-05       Impact factor: 4.432

8.  Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism.

Authors:  J H Brown; S L Brown
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

9.  Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.

Authors:  E Meller; S Kuga; A J Friedhoff; M Goldstein
Journal:  Life Sci       Date:  1985-05-13       Impact factor: 5.037

10.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

View more
  7 in total

1.  Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway.

Authors:  César Quiroz; Rafael Luján; Motokazu Uchigashima; Ana Patrícia Simoes; Talia N Lerner; Janusz Borycz; Anil Kachroo; Paula M Canas; Marco Orru; Michael A Schwarzschild; Diane L Rosin; Anatol C Kreitzer; Rodrigo A Cunha; Masahiko Watanabe; Sergi Ferré
Journal:  ScientificWorldJournal       Date:  2009-11-18

2.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

3.  Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.

Authors:  J Lappalainen; J Hietala; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  The catalepsy of blocked dopaminergic receptors.

Authors:  W R Klemm
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats.

Authors:  F Wanibuchi; S Usuda
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal.

Authors:  Thomas V Wiecki; Katrin Riedinger; Andreas von Ameln-Mayerhofer; Werner J Schmidt; Michael J Frank
Journal:  Psychopharmacology (Berl)       Date:  2009-01-24       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.